Ketorolac as an Adjuvant Agent for Postoperative Pain Control Following Arthroscopic Meniscus Surgery
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04246541|
Recruitment Status : Recruiting
First Posted : January 29, 2020
Last Update Posted : January 29, 2020
|Condition or disease||Intervention/treatment||Phase|
|Meniscus Tear, Tibial Pain, Postoperative Postoperative Complications Ketorolac Adverse Reaction Opioid Use||Drug: Ketorolac Drug: Oxycodone-Acetaminophen||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||43 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Ketorolac as an Adjuvant Agent for Postoperative Pain Control Following Arthroscopic Meniscus Surgery|
|Actual Study Start Date :||April 23, 2019|
|Estimated Primary Completion Date :||July 31, 2020|
|Estimated Study Completion Date :||December 31, 2020|
Patients will receive standard of care Percocet for post-operative pain control following meniscus debridement surgery
Patients will be discharged with oxycodone-acetaminophen (5mg-325mg) PRN for pain control after surgery.
Patients will receive IV ketorolac during surgery. They will then receive 3 days of oral ketorolac every 6 hours for pain control following surgery.
Patients will receive IV ketorolac during surgery followed by 3 days of oral ketorolac (10 mg every 6 hours) for pain control. Patients will also be given oxycodone-acetaminophen (5mg-325mg) PRN for pain not controlled with ketorolac.
- Pain levels recorded with a visual analogue scale [ Time Frame: up to 8 weeks post-operatively ]Patients will record pain levels post-operatively using a visual analogue scale (VAS) ranging from 0 as the minimum value to 100 as the maximum value. A smaller VAS value will be considered a lower pain level.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04246541
|Contact: Lakshmanan Sivasundaram, MDfirstname.lastname@example.org|
|United States, Ohio|
|UH Cleveland Medical Center||Recruiting|
|Cleveland, Ohio, United States, 44106|
|Contact: Lakshmanan Sivasundaram, MD|
|Principal Investigator:||Michael Karns, MD||University Hospitals Cleveland Medical Center|